## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Ì  | pe Response   |                  |  |  |      |            |    |   |  |  |  | 1   |   |   |  |                                  |
|--|---|------------------|--|--|------|------------|----|---|--|--|--|---|---|---|--|----------------------------------|
| Name and Address of Reporting Person*  Mann Brenda   |   |                  |  | 2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG] |      |            |    |   |  |  | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X_ Officer (give title below) VP of Research & Development |   |   |   |  |                                  |
| (Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108 |   |                  |  | 3. Date of Earliest Transaction (Month/Day/Year) 12/29/2017                    |      |            |    |   |  |  |  | VP of Re  | esearch & D   | evelopment  |  |                                  |
| (Street) WALTHAM, MA 02452   |   |                  |  | 4. If Amendment, Date Original Filed(Month/Day/Year)                           |      |            |    |   |  | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person |  |   |   |   |  |                                  |
| (City) (State) (Zip)   |   |                  |  | Table I - Non-Derivative Securities Acqui                                      |      |            |    |   |  |  | uired, Disp  | ired, Disposed of, or Beneficially Owned        |   |   |  |                                  |
| 1.Title of Security (Instr. 3)   |   |                  | 2. Transaction<br>Date<br>(Month/Day/Year) |  |      | (Instr. 8) |    | (A) or Disposed of ((Instr. 3, 4 and 5) |  | of (D  | Beneficia<br>Reported  | nt of Securiti                                  | ollowing  | Ownership<br>Form:  | 7. Nature of Indirect Beneficial               |                                  |
|  |   |                  |  | (Month/Day/Ye  | ear) | Cod        | le | V                                       | Amoun  | (A) or (D)   | Price  | (Instr. 3 a                                     | nd 4)   |   | Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4) | Ownership<br>(Instr. 4)          |
| Common   | Stock   |                  | 12/29/2017                                 |  |      | <u>J(1</u> | )  |   | 6,722  | A  | \$<br>1.01   | 18,473  |   |   | D  |                                  |
| Reminder:  | Report on a s   | separate line fo | r each class of secur<br>Table II - 1      | ities beneficial   | -    |            | F  | Personta<br>conta                       | ons wh<br>ained in                             | no respo<br>n this fo<br>splays a  | orm a  | e not requently valid                           | ction of inf<br>uired to res<br>OMB conf            | spond unle  | ess  | C 1474 (9-02)                    |
| T  | ı   |                  |  | e.g., puts, calls  | , wa | rrants,    |    |   |  |  |  |   |   | 1   |  |                                  |
| Security   | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security |                  | Execution I any                            |  |      | Number and |    | and I                                   | ate Exercisable Expiration Date onth/Day/Year) |  | An<br>Un<br>Sec  | Fitle and nount of derlying curities str. 3 and | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>Derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s<br>(Instr. 4) | Owners Form of Derivat Securit Direct or India | Beneficia Ownershi y: (Instr. 4) |
|  |   |                  |  | Code   | V    | (A) (I     |    | Date<br>Exer                            |  | Expiration Date  | on Tit   | Amount<br>or<br>le Number<br>of<br>Shares       |   |   |  |                                  |

### **Reporting Owners**

|  | Relationships |              |                              |       |  |  |  |
|--|---------------|--------------|------------------------------|-------|--|--|--|
| Reporting Owner Name / Address   |               | 10%<br>Owner | Officer                      | Other |  |  |  |
| Mann Brenda<br>C/O EYEGATE PHARMACEUTICALS, INC.<br>271 WAVERLEY OAKS ROAD, SUITE 108<br>WALTHAM, MA 02452 |               |              | VP of Research & Development |       |  |  |  |

### **Signatures**

| /s/ Robert A. Petitt, attorney-in-fact | 01/03/2018 |
|--|------------|
| **Signature of Reporting Person        | Date       |

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares were acquired under the Issuer's Employee Stock Purchase Plan on December 29, 2017 in a transaction exempt under Rule 16b- $_{3(c)}$ .

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.